Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study by EON

VIEWS: 0 PAGES: 2

JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients with hematological malignancies such as leukemia and lymphoma. The primary endpoint is defined as the rate of mortality (%) within 100 days after transplantation. For the final analysis, the historical co a style=

More Info
To top